1. Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Issue 1 (December 2016) Authors: Miner, Jeffrey; Tan, Philip; Hyndman, David; Liu, Sha; Iverson, Cory; Nanavati, Payal; Hagerty, David; Manhard, Kimberly; Shen, Zancong; Girardet, Jean-Luc; Yeh, Li-Tain; Terkeltaub, Robert; Quart, Barry Journal: Arthritis research & therapy Issue: Volume 18:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Issue 1 (December 2016) Authors: Miner, Jeffrey; Tan, Philip; Hyndman, David; Liu, Sha; Iverson, Cory; Nanavati, Payal; Hagerty, David; Manhard, Kimberly; Shen, Zancong; Girardet, Jean-Luc; Yeh, Li-Tain; Terkeltaub, Robert; Quart, Barry Journal: Arthritis research & therapy Issue: Volume 18:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Issue 1 (December 2016) Authors: Miner, Jeffrey; Tan, Philip; Hyndman, David; Liu, Sha; Iverson, Cory; Nanavati, Payal; Hagerty, David; Manhard, Kimberly; Shen, Zancong; Girardet, Jean-Luc; Yeh, Li-Tain; Terkeltaub, Robert; Quart, Barry Journal: Arthritis research & therapy Issue: Volume 18:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗